Jakob Ripshtein to become Aphria’s first Chief Commercial Officer Christelle Gedeon appointed Chief Legal Office
Leamington, Ontario – April 25, 2018 – Aphria Inc. (“Aphria” or the “Company”) (TSX: APH and US OTC: APHQF) today announced the appointment of Jakob Ripshtein as the Company’s first Chief Commercial Officer as of May 1, 2018 and Christelle Gedeon as Chief Legal Officer as of June 1, 2018. The Company is also announcing several new management appointments as Aphria continues to add depth, experience and leadership across the organization, together with the adoption of a formal governance policy regarding investments and other opportunities.
Jakob Ripshtein, Chief Commercial Officer
As Aphria’s first Chief Commercial Officer, Mr. Ripshtein will oversee the Company’s commercial, sales and marketing teams. Mr. Ripshtein most recently served as Chief Financial Officer of Diageo North America, a position he has held since 2016. In his 10 years with Diageo, he also served as President of Diageo Canada and also held a variety of Finance and Commercial roles in Canada, the United States and England. While serving as CFO and President of Diageo Canada concurrently, Mr. Ripshtein managed Diageo Canada’s overall operations and resources and strove to continually improve Diageo’s relationships with its critical stakeholders – brokers, Provincial Liquor Regulators, and Provincial and Federal authorities. Prior to Diageo, he oversaw business, sales and tax functions in the Canadian spirits, pharmaceutical and financial sectors.
Mr. Ripshtein joins Aphria’s Executive Team, reporting to the CEO, and will be based in Toronto. He will be an integral part of strategic planning in both Sales and Marketing, as well as leading various commercial business plans.
“Jakob is a tremendous addition to our leadership team and we are thrilled to welcome him to the Aphria family,” said Vic Neufeld, CEO of Aphria. “He brings an incredible track record and a depth of experience in regulated industries that will strengthen our commercial, sales and marketing operations and our entire organization. We’re continuing to add world-class talent as we build Aphria’s bench strength throughout the company”
Christelle Gedeon, H.Bsc, LL.B/B.C.L., Ph.D., Chief Legal Officer
Dr. Gedeon will join Aphria as the Company’s Chief Legal Officer. Dr. Gedeon was most recently a Partner at Fasken, where her practice focused on the life sciences industry, advising on intellectual property matters, regulated products under the Food and Drugs Act and providing transactional support. Dr. Gedeon received her LL.B./B.C.L. from McGill University and holds a Ph.D. in Clinical Pharmacology and Toxicology from the University of Toronto.
“We are delighted to bring Christelle’s extensive knowledge and experience in regulatory affairs and specifically the cannabis industry in Canada in-house,” continued Neufeld. “It’s a big win for Aphria to have someone of Christelle’s caliber on our leadership team, and we are looking forward to benefiting from her expertise and guidance as the cannabis industry continues to evolve.”
Aphria announces Vice President of Commercial Strategy, Director of Education and Training, and Director of Information Technology
Aphria is also pleased to announce the following appointments:
Aphria Co-Founder to oversee Broken Coast Cannabis
With over 20 years in commercial agricultural business, John Cervini, Co-Founder of Aphria and Vice President of Technology & Infrastructure, will oversee the operations of the Company’s subsidiary Broken Coast Cannabis Inc., in addition to his current responsibilities.
The Company is also pleased to announce that as part of its regular review and enhancement of governance practices, the board of directors (the “Board”) of the Company, upon the unanimous recommendation of the Compensation, Nominating and Governance committee (the “Committee”) of the Board, has unanimously adopted a refreshed Position Description for the Lead Independent Director and a formal Policy Regarding Investments and other Opportunities (the “Policy”) in the cannabis and related industries, each effective immediately. The Policy applies to all directors, executive officers and other designated individuals employed or retained by the Company and its subsidiaries and provides for, among other things: (i) certain considerations regarding potential corporate opportunities of the Company, (ii) additional requirements for investments in other companies operating in the cannabis and related industries, (iii) approval and other requirements for new and existing directorships within the cannabis and related industries, and (iv) sanctions for any breach or non-compliance with the Policy.
Vic Neufeld, the Chief Executive Officer and Chairman of the Board, stated, “our Company is committed to attracting and retaining new leaders and pursuing best practices for governance on our Board and within our management team. As we continue to execute on our existing strategic plan for the Company, and we increasingly interact with governments, government agencies and other strategic partners, both within Canada and globally, the requirement for good governance has never been more important to the Company in achieving its corporate objectives. We look forward to fulfilling a leadership position in governance in the emerging cannabis industry in Canada. “
Dennis Staudt, the lead independent director of the Board added, “I look forward to working more closely with the independent directors on the Board on behalf of our stakeholders.”
The Company also announced that the Committee is currently interviewing and considering prospective candidates for the appointment or election of an additional independent and qualified director to the Board and expects to add such new independent director to its slate of management nominees for election to the Board at its next annual and general meeting of shareholders.
We Have a Good Thing Growing.
Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.
For more information, visit: aphria.ca
For media inquiries please contact:
Director of Communications
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations, estimated margins, expectations with respect to actual production volumes, expectations for future growing capacity and costs, the completion of any capital project or expansions, and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.